Cambrian Biopharma is a biotechnology company focused on developing treatments that target the underlying biology of aging to extend human healthspan. They aim to create a pipeline of therapeutics addressing the various hallmarks of aging and age-related diseases. By targeting these hallmarks, Cambrian Biopharma seeks to develop therapies that can potentially delay, prevent, or treat multiple age-related diseases simultaneously. The company’s strategy involves acquiring, licensing, and investing in early-stage biotechnology companies and assets that target the fundamental biology of aging. They support these assets through their development, preclinical, and clinical phases to create innovative treatments for age-related diseases.Cambrian Biopharma was founded in 2021 by James Peyer. Cam-5746 is a lead compound meaning it has pharmacological or biological activity likely to be therapeutically useful, but may nevertheless have suboptimal structure that requires further modfication. Developers believe CAM-5746 may be used to improve proteostatsis and have applications in autoimmune disease.